Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-16T01:19:17.518Z Has data issue: false hasContentIssue false
  • English
  • Français

Physical health management in psychiatric settings

Published online by Cambridge University Press:  16 April 2020

M. De Hert ,
R. van Winkel ,
A. Silic ,
D. Van Eyck  and
J. Peuskens
M. De Hert*
Affiliation:
University Psychiatric Center, Katholieke Universiteit Leuven, campus Kortenberg, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium
R. van Winkel
Affiliation:
University Psychiatric Center, Katholieke Universiteit Leuven, campus Kortenberg, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium Department of Psychiatry and Neuropsychology, EURON, South Limburg Mental Health Research and Teaching Network, Maastricht University, Maastricht, The Netherlands
A. Silic
Affiliation:
Psychiatry Hospital Sveti Ivan, Zagreb, Croatia
D. Van Eyck
Affiliation:
University Psychiatric Center, Katholieke Universiteit Leuven, campus Kortenberg, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium
J. Peuskens
Affiliation:
University Psychiatric Center, Katholieke Universiteit Leuven, campus Kortenberg, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium
*
*Correspondence. Tel.: +32 27 5805 11. E-mail address: [email protected]
Get access

Abstract

Severe mental disorders have a chronic course associated with a high risk for co-morbid somatic illnesses and premature mortality, but despite this increased risk, general health care needs in this population are often neglected. Over recent years, several groups have developed screening and monitoring guidelines for metabolic and cardiovascular risk assessment in patients treated with antipsychotics. The psychiatrist needs to be aware of the potential metabolic side-effects of antipsychotic medication and to include them in the risk/benefit assessment when choosing a specific antipsychotic. He should also be responsible for the implementation of the necessary screening assessments and referral for treatment of any physical illness. Multidisciplinary assessment of psychiatric and medical conditions is needed. The somatic treatments offered to people with severe and enduring mental illness should be at par with general health care in the non-psychiatrically ill population. In our University Centre, a structured and elaborate screening and monitoring protocol was introduced in late 2003. This paper describes the practical aspects of this monitoring protocol and the results obtained 4 years after its implementation.

Keywords

SchizophreniaSevere mental disordersPhysical healthHealth screeningAntipsychotic therapy
Type
Research Article
Information
European Psychiatry , Volume 25 , Issue S2: Physical health in patients with schizophrenia: current knowledge and practical recommendations , June 2010 , pp. S22 - S28
Copyright
Copyright © 2010 Elsevier Masson SAS

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allison, D.B.Mackell, J.A.McDonnell, D.D.The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565–567CrossRefGoogle ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601CrossRefGoogle Scholar
Aronne, L.J.Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001; 62(Suppl. 23): 13–22Google ScholarPubMed
Awad, A.G.Voruganti, L.N.Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scale. Schizophr Res 2004; 70: 63–67CrossRefGoogle ScholarPubMed
Awad, G.A.Antipsychotic medication: compliance and attitudes towards treatment. Curr Opinion Psychiatry 2004; 7: 75–80CrossRefGoogle Scholar
Barnett, A.H.Mackin, P.Chaudhry, I.Farooqi, A.Gadsby, R.Heald, A., et al.Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol 2007; 21: 357–373CrossRefGoogle ScholarPubMed
Bebbington, P.E.Le Lay, A.Hansen, K.Understanding and explaining adverse events in schizophrenia. Schizophr Res 2006; 81(Suppl.): 25–26Google Scholar
Brown, S.Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502–508CrossRefGoogle ScholarPubMed
Brown, S.Inskip, H.Barraclough, B.Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212–217CrossRefGoogle ScholarPubMed
Buckley, P.F.Miller, dD.Singer, B.Arena, J.Stirewalt, E.M.Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 2005; 79: 281–288CrossRefGoogle ScholarPubMed
Caro, J.J.Ward, A.Levinton, C.Robinson, K.The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002; 63: 1135–1139CrossRefGoogle ScholarPubMed
Casey, D.E.Haupt, D.W.Newcomer, J.W.Henderson, D.C.Sernyak, M.J.Davidson, M., et al.Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65(Suppl. 7): 4–18Google ScholarPubMed
Citrome, L.Yeomans, D.Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005; 19: 102–109CrossRefGoogle ScholarPubMed
Citrome, L.L.Jaffe, A.B.Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003; 37: 1849–1857CrossRefGoogle ScholarPubMed
Cohn, T.A.Sernyak, M.J.Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 492–501CrossRefGoogle ScholarPubMed
Correll, C.U.From receptor pharmacology to improved outcomes: individualizing the selection, dosing and switching of antipsychotics. Eur Psychiatry 2010; 25: S12–S21CrossRefGoogle Scholar
De Hert, M.Dekker, J.M.Wood, D.Kahl, K.G.Moller HJ, Cardiovascular Disease and Diabetes in People with Severe Mental Illness. Position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009; 24: 412–424CrossRefGoogle Scholar
De Hert, M.Hanssens, L.van Winkel, R.Wampers, M.Van Eyck, D.Scheen, A., et al.Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care 2006; 29: 2329–2330CrossRefGoogle ScholarPubMed
De Hert, M.Hanssens, L.van Winkel, R.Wampers, M.Van Eyck, D.Scheen, A., et al.A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007; 33: 823–830CrossRefGoogle ScholarPubMed
De Hert, M.Kalnicka, D.van Winkel, R.Wampers, M.Hanssens, L.Van Eyck, D., et al.Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2006; 67: 1889–1896CrossRefGoogle ScholarPubMed
De Hert, M.Peuskens, B.van Winkel, R.Kalnicka, D.Hanssens, L.Van Eyck, D., et al.Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE. Schizophr Res 2006; 88: 222–226CrossRefGoogle ScholarPubMed
De Hert, M.Van Eyck, D.de Nayer, A.Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006; 21(Suppl. 2): S11–S15CrossRefGoogle ScholarPubMed
De Hert, M.Van Eyck, D.Hanssens, L.Peuskens, H.Thys, E.Wampers, M., et al.Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry 2006; 21: 224–226CrossRefGoogle ScholarPubMed
De Hert, M.van Winkel, R.Van Eyck, D.Hanssens, L.Wampers, M.Scheen, A., et al.Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2006; 2: 14CrossRefGoogle ScholarPubMed
De Hert, M.A.van Winkel, R.Van Eyck, D.Hanssens, L.Wampers, M.Scheen, A., et al.Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87–93CrossRefGoogle ScholarPubMed
De Nayer, A.De Hert, M.Scheen, A.Van Gaal, L.Peuskens, J.Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract 2005; 9: 130–137CrossRefGoogle ScholarPubMed
Dickerson, F.B.Brown, C.H.Daumit, G.L.Fang, L.Goldberg, R.W.Wohlheiter, K., et al.Health status of individuals with serious mental illness. Schizophr Bull 2006; 32: 584–589CrossRefGoogle ScholarPubMed
Dixon, L.Postrado, L.Delahanty, J.Fischer, P.J.Lehman, A.The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999; 187: 496–502CrossRefGoogle ScholarPubMed
Fleischhacker, W.W.Cetkovich-Bakmas, M.De Hert, M.Hennekens, C.H.Lambert, M.Leucht, S., et al.Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry 2008; 69: 514–519CrossRefGoogle ScholarPubMed
Hanssens, L.De Hert, M.Kalnicka, D.van Winkel, R.Wampers, M.Van Eyck, D., et al.Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int Clin Psychopharmacol 2007; 22: 43–49Google ScholarPubMed
Haupt, D.W.Rosenblatt, L.C.Kim, E.Baker, R.A.Whitehead, R.Newcomer, J.W.Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009; 166: 345–353CrossRefGoogle ScholarPubMed
Heald, A.Physical health in schizophrenia: a challenge for antipsychotic therapy. Eur Psychiatry 2010; 25: S6–S11CrossRefGoogle ScholarPubMed
Henderson, D.C.Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16: 77–89CrossRefGoogle ScholarPubMed
Hennekens, C.H.Hennekens, A.R.Hollar, D.Casey, D.E.Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115–1121CrossRefGoogle ScholarPubMed
Holt, R.I.Peveler, R.C.Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetologia 2006; 49: 1467–1476CrossRefGoogle ScholarPubMed
Hoschl, C.Importance of physical health in patients with schizophrenia. Eur Psychiatry 2010; 25: S1–S2CrossRefGoogle ScholarPubMed
Jin, H.Meyer, J.M.Jeste, D.V.Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71: 195–212CrossRefGoogle ScholarPubMed
Leucht, S.Burkard, T.Henderson, J.Maj, M.Sartorius, N.Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116: 317–333CrossRefGoogle ScholarPubMed
Marder, S.R.Essock, S.M.Miller, A.L.Buchanan, R.W.Casey, D.E.Davis, J.M., et al.Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–1349CrossRefGoogle ScholarPubMed
McEvoy, J.P.Meyer, J.M.Goff, D.C.Nasrallah, H.A.Davis, S.M.Sulli-Van, L., et al.Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32CrossRefGoogle ScholarPubMed
Melkersson, K.Dahl, M.L.Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64: 701–723CrossRefGoogle ScholarPubMed
Meyer, J.M.Nasrallah, H.A.Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Publishing; 2003; 13–14Google Scholar
Montejo, A.L.The need for routine physical healthcare in schizophrenia. Eur Psychiatry 2010; 25: S3–S5CrossRefGoogle Scholar
Muir-Cochrane, E.Medical co-morbidity risk factors and barriers to care for people with schizophrenia. J Psychiatr Ment Health Nurs 2006; 13: 447–452CrossRefGoogle ScholarPubMed
Newcomer, J.W.Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(Suppl. 1): 1–93CrossRefGoogle ScholarPubMed
Newcomer, J.W.Nasrallah, H.A.Loebel, A.D.The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol 2004; 24(5 Suppl. 1): S1–S6CrossRefGoogle ScholarPubMed
Osby, U.Correia, N.Brandt, L.Ekbom, A.Sparen, P.Mortality and causes of death in schizophrenia in Stockholm county. Sweden. Schizophr Res 2000; 45: 21–28CrossRefGoogle ScholarPubMed
Scheen, A.Van Winkel, R.De Hert, M.Traitement neuroleptique et troubles metabolique. Med Mal Metabol 2008; 2: 593–599Google Scholar
Scheen, A.J.De Hert, M.Drug-induced diabetes mellitus: the exemple of atypical antipsychotics. Rev Med Liege 2005; 60: 455–460Google ScholarPubMed
Scheen, A.J.De Hert, M.A.Risque de diabete sucre sous antipsychotiques atypiques. Med Hyg (Geneve) 2004; 62: 1591–1596Google Scholar
Scheen, A.J.De Hert, M.A.Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007; 33: 169–175CrossRefGoogle ScholarPubMed
Sernyak, M.J.Leslie, D.L.Alarcon, R.D.Losonczy, M.F.Rosenheck, R.Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561–566CrossRefGoogle ScholarPubMed
Strassnig, M.Brar, J.S.Ganguli, R.Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr Res 2003; 62: 73–76CrossRefGoogle ScholarPubMed
Strassnig, M.Brar, J.S.Ganguli, R.Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. Schizophr Res 2005; 75: 425–432CrossRefGoogle ScholarPubMed
van Winkel, R.De Hert, M.Applicability of the OGTT in assessing prevalence and incidence of DM in schizophrenia: response to Cohen. J Clin Psychiatry 2007; 68: 1308–1309CrossRefGoogle Scholar
van Winkel, R.De Hert, M.Van Eyck, D.Hanssens, L.Wampers, M.Scheen, A., et al.Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006; 67: 1493–1500CrossRefGoogle ScholarPubMed
van Winkel, R.De Hert, M.Van Eyck, D.Hanssens, L.Wampers, M.Scheen, A., et al.Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342–348CrossRefGoogle Scholar
van Winkel, R.De Hert, M.Wampers, M.Van Eyck, D.Hanssens, L.Scheen, A., et al.Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008; 69: 472–479CrossRefGoogle ScholarPubMed
Voruganti, L.P.Punthakee, Z.Van Lieshout, R.J.MacCrimmon, D.Parker, G.Awad, A.G., et al.Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central- South Ontario (DiSCO) study. Schizophr Res 2007; 96: 215–222CrossRefGoogle Scholar
Weiden, P.J.Mackell, J.A.McDonnell, D.D.Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51–57CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.